Clinical Validation Study for CPM Device

NCT05445206 | Completed Results FDA Device

• 1 other identifier: Resp CPM Validation
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This study is designed to be a clinical validation study to ready the CPM System for FDA 510(k) submission. This study will be conducted as a prospective non-randomized. The study is non-significant risk since the CPM Device is noninterventional and noninvasive. The study is primarily designed to validate the accuracy of the respiration rate and the changes in relative tidal volume. All participants will be fitted with both the CPM Device as well as reference devices (capnography and ECG). Participants will be randomized between 4 procedures (A-D) which will determine the order of 18 exercises. Each exercise has about 2 minutes of device recording and two minutes of rest. Each exercise contains two positions: sitting up for one minute and lying down for one minute. For some exercises, the participant will be instructed to breathe at a certain rate (assisted by a metronome). For other exercises, the participants will breathe at a normal rate but change how deep the are breathing. For exercise 18, all capnography reference devices will be removed, and an ECG reference device will be placed. After exercise 18, the participant will have all devices removed and the study visit will terminate. The participant will receive a safety follow-up call about 1 week after their visit.

Conditions

Heart Failure

Outcome Measures

Primary Outcomes (2)

• Accuracy of CPM System Calculated RR Versus Reference Device Via Percent of Error Accuracy of Respiration Rate

  Accuracy of CPM System calculated RR versus reference device reported as percentage of respiration rate error within +/- breath rates per minute. Acceptance for clinical utility is \>= 85%. Percentage of respiration rate error within ± 2bpm. Acceptance criteria for clinical utility is \>= 85%. The percentage of respiration rate within ± 2brpm was calculated by data points, regardless of its rate and breathing condition, which the CPM System did not screen, therefore reporting the numeric values. Each data point will produce binary result (True or False) if the error is within ± 2 brpm. Assuming this binary result follows a binominal distribution, its confidence interval is also calculated.

  up to 3 hours

• Root Mean Squared Error (RMSE) of Respiration Rates From the CPM System vs Reference Device for Metronome Guided Breathing and Non-metronome Guided Breathing.

  Root mean square (RMS) of residual relative error of relative tidal volume. Acceptance criteria for clinical utility is \<= 35%. First, the subject-specific linear fitting is performed after taking the natural log of both CPM's rTV and reference TV. Then, the residual errors in rTV after the fitting were calculated. Finally, all subject's residual errors are pooled together to calculate the root mean squared (RMS) residual relative errors. The confidence interval was calculated assuming the square of this error follows Chi-square distribution. This error characterized in a log-log domain is converted back to characterize a relative accuracy by taking an exponential of natural constant followed by subtraction of one. The RMS of residual error in % is characterized in this way because the linear fitting in the log-log domain and its residual errors represents faithful relative residual error regardless of an absolute value of TV.

  up to 3 hours

Secondary Outcomes (3)

• Accuracy of CPM System Calculated Respiration Rate Versus Reference Device, Reported as Root Mean Squared (RMS) Error

  up to 3 hours

• CPM's ECG Metrics Compared to Reference Device Lead II ECG Metrics (Results Displayed as % Comparasion)

  up to 3 hours

• Test Device Skin Temperature vs Reference Device Skin Temperature Comparison

  up to 3 hours

Study Arms (1)

Health Adult

EXPERIMENTAL

The target population is healthy adult volunteers who do not have preexisting heart or lung conditions or illness. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders.

Device: CardioPulmonary Management Device (CPM)

Interventions

CardioPulmonary Management Device (CPM) DEVICE

CPM device is used in tangent with reference capnography device.

Health Adult

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults over the age of 18 and who are willing and able to give informed consent
• Willing and able to participate in all activities related to this study, including trimming chest hair and wearing a reference device and the CPM wearable device
• Volunteers of any race, any gender
• Range of physiques
• Healthy

You may not qualify if:

• Injury or skin disturbance in the area of the test device
• Allergies or sensitivities to silicone/acrylic-based adhesive
• Pregnant, method of assessment at discretion of PI
• Currently smokes cigarettes
• Has known respiratory conditions that might prevent them from following the study procedure such as:
• Flu
• Pneumonia/bronchitis
• Shortness of breath/respiratory distress
• Respiratory or lung surgery
• Emphysema, COPD, lung disease
• Has self-reported heart or cardiovascular conditions such as chest pain, AFib, CHF, cardiomyopathy, or other conditions that could interfere with cardiopulmonary function
• Has other self-reported health conditions that could interfere with the breathing patterns and exercises detailed in the protocol (including wearing a capnography mask)

Sponsors & Collaborators

• Analog Device, Inc.: lead
• Mayo Clinic: collaborator

Study Sites (1)

Mayo Clinic Hospital

Rochester, Minnesota, 55905-0001, United States

Location

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases

Results Point of Contact

• Title: Emily Wycallis
• Organization: Analog Devices, Inc.

emily.wycallis@analog.com

9784351644

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Masking Details: The individuals who annotate the capnography waveform are blinded between the reference strip and the test device strip.
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Comparison between test device and reference device

Study Record Dates

• First Submitted: June 30, 2022
• First Posted: July 6, 2022
• Study Start: March 2, 2022
• Primary Completion: July 6, 2022
• Study Completion: July 6, 2022
• Last Updated: June 12, 2024
• Results First Posted: June 12, 2024

Record last verified: 2024-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)